Characterization of orofacial features in sclerodermatous chronic graft-versus-host disease

被引:1
|
作者
Bajonaid, Amal [1 ,12 ]
Guntaka, Praveen Kumar [2 ]
Harper, Matthew [3 ,4 ]
Cutler, Corey [5 ]
Duncan, Christine [6 ]
Villa, Alessandro [7 ,8 ,9 ]
Sroussi, Herve Y. [10 ,11 ]
Woo, Sook-Bin [10 ,11 ]
Treister, Nathaniel S. [10 ,11 ]
机构
[1] Jazan Univ, Coll Dent, Jazan, Saudi Arabia
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA
[4] Boston Childrens Hosp, Dept Dent, Boston, MA USA
[5] Dana Farber Canc Inst, Div Stem Cell Transplantat & Cellular Therapy, Boston, MA USA
[6] Dana Farber Boston Childrens Canc & Blood Disorder, Boston, MA USA
[7] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA USA
[8] Herbert Wertheim Coll Med, Miami, FL USA
[9] Miami Canc Inst, Miami, FL USA
[10] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA
[11] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA USA
[12] Jazan Univ, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Al Maarefah Rd, Jazan, Saudi Arabia
关键词
face; graft-versus-host disease; oral cavity; sclerosis; CONSENSUS DEVELOPMENT PROJECT; RISK-FACTORS; PHOTOBIOMODULATION THERAPY; CELL TRANSPLANTATION; ORAL INVOLVEMENT; CLINICAL-TRIALS; CHRONIC GVHD; RECOMMENDATIONS; CRITERIA; PATHOGENESIS;
D O I
10.1111/odi.14932
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BackgroundChronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (alloHCT). The sclerodermatous form of cGVHD can be particularly debilitating; however, orofacial sclerodermatous involvement remains poorly described. ObjectiveTo characterize orofacial features of sclerodermatous cGVHD in a single center cohort of patients who underwent alloHCT. Study DesignRetrospective data were collected from electronic medical records and analyzed descriptively. ResultsThere were 39 patients who received alloHCT between 1993 and 2017 and developed orofacial sclerodermatous cGVHD. Concomitant cutaneous sclerodermatous cGVHD was common (n = 20, 51%). Orofacial sclerodermatous cGVHD features included fibrous bands of the buccal mucosa (n = 23, 59%), limited mouth opening (n = 19, 54%), perioral fibrosis (n = 8, 21%), and focal gingival recession (n = 4, 10%). Oral mucosal fibrosis was observed at the site of active or resolved chronic lichenoid inflammation in 30 patients, with all but two also presenting with a history of ulcerations. Management included jaw stretching exercises (n = 10; 6 stable/improved), surgery (n = 3; 2 improved), and intralesional corticosteroid injections (n = 2; 2 improved). ConclusionsOrofacial involvement with sclerodermatous cGVHD can present with multiple manifestations including fibrous banding, limited mouth opening, perioral fibrosis, and focal gingival recession. Surgical and non-surgical management strategies may improve clinical function and reduce morbidity.
引用
收藏
页码:5082 / 5090
页数:9
相关论文
共 50 条
  • [1] CHRONIC SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE
    MULLERSERTEN, B
    VAKILZADEH, F
    HAUTARZT, 1994, 45 (11): : 772 - 775
  • [2] A pediatric case of sclerodermatous chronic graft-versus-host disease
    Terasaki, K
    Kanekura, T
    Setoyama, M
    Kanzaki, T
    PEDIATRIC DERMATOLOGY, 2003, 20 (04) : 327 - 331
  • [3] Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease
    Marcellus, DC
    Altomonte, VL
    Farmer, ER
    Horn, TD
    Freemer, CS
    Grant, J
    Vogelsang, GB
    BLOOD, 1999, 93 (01) : 66 - 70
  • [4] Sclerodermatous chronic graft-versus-host disease: a report of four cases
    Tolland, JP
    Jones, FCG
    Bingham, EA
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 : 41 - 42
  • [5] Pulp Obliteration in a Patient with Sclerodermatous Chronic Graft-versus-Host Disease
    Ferreira Gomes, Camilla Borges
    Treisten, Nathaniel Simon
    Millen, Brian
    Armand, Philippe
    Friedland, Bernard
    JOURNAL OF ENDODONTICS, 2016, 42 (04) : 678 - 680
  • [6] Imatinib mesylate in the treatment of sclerodermatous chronic graft-versus-host disease
    Yakoub-Agha, I.
    Magro, L.
    Catteau, B.
    Coiteux, V.
    Terriou, L.
    Jouet, J. P.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S190 - S190
  • [7] Prevention of Murine Sclerodermatous Chronic Graft-Versus-Host Disease by Rapamycin
    Belle, Ludovic
    Binsfeld, Marilene
    Dubois, Sophie
    Hannon, Muriel
    Caers, Jo
    Briquet, Alexandra
    Menten, Catherine
    Beguin, Yves
    Humblet, Stephanie
    Baron, Frederic
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S317 - S318
  • [8] Hedgehog Signaling in Murine Chronic Sclerodermatous Graft-Versus-Host Disease
    Zerr, Pawel
    Palumbo-Zerr, Katrin
    Distler, Alfiya
    Tomcik, Michal
    Vollath, Stefan
    Munoz, Louis E.
    Beyer, Christian
    Dees, Clara
    Egberts, Friederike
    Tinazzi, Ilaria
    Del Galdo, Francesco
    Distler, Oliver
    Schett, Georg
    Spriewald, Bernd M.
    Distler, Joerg H. W.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S644 - S644
  • [9] SCLERODERMATOUS CHRONIC GRAFT-VERSUS-HOST DISEASE - ANALYSIS OF 7 CASES
    CHOSIDOW, O
    BAGOT, M
    VERNANT, JP
    ROUJEAU, JC
    CORDONNIER, C
    KUENTZ, M
    WECHSLER, J
    ANDRE, C
    TOURAINE, R
    REVUZ, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (01) : 49 - 55
  • [10] Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice
    Belle, L.
    Binsfeld, M.
    Dubois, S.
    Hannon, M.
    Caers, J.
    Briquet, A.
    Menten, C.
    Beguin, Y.
    Humblet-Baron, S.
    Baron, F.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S63 - S64